This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It was at this time they set their site at Sandwich in the UK, initially just to finish processing compounds imported from America, but due to tariffs on imported products the company rapidly expanded the plant to accommodate producing medicines from scratch. Likewise, tanezumab, an anti-osteoarthritic, failed in trials.
Pharmaceuticalcompanies, regulatory agencies and governments are becoming increasingly concerned about fraud and counterfeiting throughout the pharmaceutical supply chain, especially with the cost of drugs going up. “Europe is favouring 2D data matrix codes to encode information while the US is tending more towards RFID.”
After the outbreak of any epidemic or pandemic, all the responsibilities come on the shoulders of pharmaceuticalcompanies. With unprecedented diseases lurking on the corner, pharmaceuticalcompanies, are now obligated to widen their conventional horizons and look for substitute practices in their drug development strategies.
Large-molecule drugs such as biologics are particularly sensitive to foreign contamination and E&L interaction, making these issues key concerns for pharmaceuticalcompanies. In addition, packaging components are not entirely manufactured in a clean room environment, making them a potential source of exogenous contamination.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content